Evidence map›Paper›PMID 39846134›Full record

ReviewJournal of the International AIDS Society2025

A global review of national guidelines of post-exposure prophylaxis for the prevention of HIV.

Marcus Maisano, Daniel Tran, Virginia Macdonald, Rachel C Baggaley, Nathan Ford, Cheryl C Johnson, Ying Zhang, Jason J Ong

Abstract readReview
In one paragraph

Review in Journal of the International AIDS Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marcus MaisanoMelbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.ORCID https://orcid.org/0009-0004-9123-4001
Daniel TranMelbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia.
Virginia MacdonaldGlobal HIV, Hepatitis and STI Programmes, World Health Organization, Geneva, Switzerland.ORCID https://orcid.org/0000-0001-5798-6059
Rachel C BaggaleyGlobal HIV, Hepatitis and STI Programmes, World Health Organization, Geneva, Switzerland.
Nathan FordGlobal HIV, Hepatitis and STI Programmes, World Health Organization, Geneva, Switzerland.
Cheryl C JohnsonGlobal HIV, Hepatitis and STI Programmes, World Health Organization, Geneva, Switzerland.
Ying ZhangMelbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0001-7717-5691
Jason J OngMelbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0001-5784-7403

Funding

The Australian National Health and Medical Research Council (NHMRC) Emerging Leadership Investigator GNT1193955World Health Organization 001
6 · The paper itself

Abstract

introductionThe World Health Organization (WHO) recommends the use of antiretroviral drugs as post-exposure prophylaxis (PEP) for preventing HIV acquisition for occupational and non-occupational exposures. To inform the development of global WHO recommendations on PEP, we reviewed national guidelines of PEP for their recommendations.

methodsPolicies addressing PEP from 38 WHO HIV priority countries were obtained by searching governmental and non-governmental websites and consulting country and regional experts; these countries were selected based on HIV burden, new HIV acquisitions and the number of HIV-associated deaths. We reviewed national guidelines to collate data on where PEP can be offered, who can prescribe PEP, PEP eligibility, recommended drug regime, linkage to other interventions, recommended investigations prescribed with PEP, HIV self-test recommendation related to PEP and stopping rules for PEP.

resultsIn total, 46 guidelines from January 2010 to May 2023 across 36 countries were included, with 70% of documents published during or after 2020. There was significant variation across national guidelines regarding where PEP can be accessed and who can provide or prescribe PEP. Six countries (17%) described being able to access PEP from a primary care facility, four countries (11%) from hospitals and two (6%) from community-based services. Only three countries (8%) specifically considered dispensing PEP by professionals other than doctors (e.g. nurses). None mentioned pharmacists as prescribers. We found a lack of consistency across countries regarding who is eligible for PEP, regimens used, interventions integrated into PEP provision and recommended investigations for PEP users. No country guidance provided considerations on using HIV self-tests for starting or stopping PEP. DISCUSSION: Despite PEP being recommended for more than three decades, many national policies were lacking in terms of PEP guidance. There are opportunities for countries to update and optimize guidance to consider ways to improve the accessibility of PEP. Greater efforts are needed to support the development of global consensus on how best to implement and integrate PEP, as well as how to include decentralization and task-sharing to achieve sufficient scale for impact.

conclusionsImproving timely access to PEP and promoting PEP adherence could help contribute to reducing the incidence of HIV globally.

Indexed as

Anti-HIV AgentsHIV InfectionsPost-Exposure ProphylaxisPractice Guidelines as TopicGlobal HealthHumansWorld Health OrganizationAnti-HIV AgentsHIVnational guidelinesPEPpost‐exposure prophylaxispreventionreview

Identifiers

PMID39846134
PMCPMC11755062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.